Testing a Smartphone App That Predicts Heart Attack and Stroke Risk

Trial details

Who runs it

Stanford University

Trial code

NCT07735338

Record updated

30 July 2026

Original description

To assess the diagnostic accuracy of a smartphone application in predicting heart attack or stroke within 3-4 days in high-risk patients.Read full original descriptionShow less

Prospective Study of the Diagnostic Accuracy of a Smartphone Application to PREDICT Real-Time Cardiovascular Risk for Heart Attack and Stroke (PREDICT-HS)

To assess the diagnostic accuracy of a smartphone application in predicting heart attack or stroke within 3-4 days in high-risk patients.

Inclusion: Be able to provide electronic or written informed consent and be able to effectively communicate and understand the study procedures, risks, and required activities; Age 40 to 79 years; Be willing to wear a smartwatch continuously for 18 months and comfortable with using wearable devices or other technologies that monitor their data over time; Established ASCVD or at an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as anyone of the following:; Evidence of atherosclerotic CAD on CT or invasive coronary angiogram defined as a coronary artery stenosis ≥ 20% but <50% in the left main coronary artery or a stenosis ≥ 20% but <70% in any other major coronary artery; Coronary artery calcium score ≥ 100 Agatston units; High estimated10-year ASCVD risk ≥ 20% by pooled cohort equation; Intermediate estimated 10-year ASCVD risk 7.5% to <20% by pooled cohort equation with at least 2 of the following risk-enhancing factors:; A first degree relative with history of premature ASCVD (males, age <55 years; females, age <65 years); History of premature menopause before age 40; History of maternal pregnancy complications (defined as a history of either preeclampsia, gestational hypertension, or gestational diabetes); South Asian ancestry; Chronic inflammatory disorders (defined as either rheumatoid arthritis, systemic lupus erythematosus, psoriasis covering ≥10% of body surface area, Crohn's disease, ulcerative colitis, or HIV/AIDS); High-sensitivity C-reactive protein (hsCRP) ≥2 mg/L documented in the 12 months preceding the screening visit, and, in absence of any underlying acute or inflammatory conditions; Lipoprotein (a) ≥50 mg/dL or ≥125 nmol/L at any time before the screening visit; Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2; Ankle branchial index (ABI) <0.9 with no symptoms of intermittent claudication; Metabolic syndrome: increased waist circumference, elevated triglycerides, elevated blood pressure, elevated glucose, and low HDL-C are factors; Diabetes.

Exclusion: Cognitive impairment; Neurological disorders that would impair their ability to provide informed consent or adhere to study protocols; Metastatic cancer or active cancer undergoing chemotherapy; Terminal illness; Current or past major psychiatric disorders (e.g., schizophrenia, bipolar disorder, severe depression) that could affect physiological or biometric data; Surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study; The 10-year ASCVD risk <7.5%; Elevated troponin at baseline; Pregnant women or women of childbearing potential not using contraception; Unwillingness or inability to comply with study procedures, including adherence to study visits, fasting blood draws and compliance with study protocol; Residing in an inpatient facility or bedbound.

ClinicalTrials.gov NCT07735338